Autobahn: fine-tuning thyroid agonism to remyelinate axons
Arch-incubated remyelination play Autobahn launches with $76M series B
Autobahn, which launched with a $76 million series B Tuesday, joins at least six other companies with disclosed remyelination programs for multiple sclerosis. But the biotech thinks its prodrug, slated to enter the clinic next year, has a stronger genetic rationale than competing programs.
Arch Venture Partners incubated the biotech and co-led the untranched round with Cowen Healthcare Investments.
Arch’s Keith Lenden is president, COO and co-founder of Autobahn Therapeutics.
Also participating in the round are BVF Partners, Biogen Inc. (NASDAQ:BIIB), Bristol Myers Squibb Co. (NYSE:BMY), Pfizer Ventures, Invus, Section 32, Samsara BioCapital